Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Jumps 1,421.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totaling 89,977 shares, a growth of 1,421.2% from the September 15th total of 5,915 shares. Based on an average daily volume of 32,888 shares, the days-to-cover ratio is currently 2.7 days. Currently, 6.1% of the shares of the stock are sold short.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of GNOM stock opened at $68.75 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $40.17 and a fifty-two week high of $74.19. The stock’s fifty day moving average is $64.48 and its two-hundred day moving average is $54.66. The firm has a market capitalization of $101.75 million, a P/E ratio of -29.38 and a beta of 1.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in shares of Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares during the last quarter. Polaris Financial Partners acquired a new position in Global X Genomics & Biotechnology ETF during the third quarter worth $1,067,000. Wealth Management Partners LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the 1st quarter valued at $244,000. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter worth $257,000. 56.95% of the stock is currently owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.